Variant · Fusion
ABL1 Fusion
CI-VAR-00001245Explore in graph →CIViC 2660
Curated evidence
Evidence by cancer (10 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33357483
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| B Lymphoblastic Leukemia/Lymphoma4 | ||||||||
| NUP214::ABL1 Fusion | (prognostic) | Prognostic | B | Supports Better Outcome | 3 | accepted | EID9148A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-… (full text at CIViC) PMID 33357483 · den Boer et al., 2021 · Open in CIViC | civic |
| NUP214::ABL1 Fusion | Dasatinib + ImatinibSubstitutes | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12385Functional activity and treatment response were evaluated for several fusions identified in patients with gene expression profiles showing BCR::ABL1-like B-ALL. Phosphoflow on leukemic samples from 2 … (full text at CIViC) PMID 22897847 · Roberts et al., 2012 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available